PrEP
PreclinicalSmall molecule
PrEP is one of 47 small molecule programs targeting Telemedicine. It is currently in Preclinical.
3
Indications
18
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
27 competitors in Prophylaxis
#DrugCompanyPhaseTrials
1Lovenox
SanofiApproved
Bayer Aspirin
BayerApproved
Eliquis
Bristol-Myers SquibbApproved
Cymbalta
Jazz PharmaceuticalsApproved
Xarelto
WWim Janssens
Approved
Coreg
Akero TherapeuticsApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cabenuva
GSKPhase 3
Lovenox
SanofiPhase 3
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Prophylaxis3 trials
Women3 trials
8 more indications
HIV Prevention1 trial
Effectiveness1 trial
Female1 trial
IPREP Study #2: Evaluating Enhanced PrEP Packages for Young Female Sex Workers in Kisumu, Kenya
Completed·—·N/A·NCT03988387·200 enrolled
Pre-Exposure Prophylaxis (PrEP)1 trial
Telemedicine1 trial
Providing Suboxone and PrEP Using Telemedicine
Completed·—·N/A·NCT04521920·17 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PrEP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Washington